Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06712355 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
A Phase 3 study of Extensive-stage Small-cell Lung Cancer, sponsored by BioNTech SE.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 621
- Enrollment target
- 20
- Study locations
NCT06712355 is a Phase 3 study of Extensive-stage Small-cell Lung Cancer that is actively recruiting participants, run by BioNTech SE. The registered enrollment target is 621 participants, above the 151-participant average among 25 other Extensive-stage Small-cell Lung Cancer trials with a reported enrollment target (311% higher). The trial reports 20 study locations across 12 states.
The verdict
NCT06712355, a Phase 3 study of Extensive-stage Small-cell Lung Cancer, is actively recruiting participants, sponsored by BioNTech SE.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 621 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase III, multisite, randomized, double-blinded study to investigate pumitamig (BNT327) combined with chemotherapy (etoposide/carboplatin) compared to atezolizumab combined with chemotherapy (etoposide/carboplatin) for the treatment of participants with previously untreated extensive-stage small-cell lung cancer (ES-SCLC).
Conditions Studied
Interventions
- DRUG Atezolizumab
- DRUG Pumitamig
- DRUG Etoposide
- DRUG Carboplatin (or cisplatin if carboplatin is not tolerated)
Study Locations (20)
Ohio
- Cleveland Clinic - Akron General Hematology & Oncology - Akron
- Cleveland Clinic Mercy Hospital Cancer Center - Canton
- The Christ Hospital Cancer Center - Cincinnati
- University Hospitals Cleveland Medical Center - Cleveland
- The Cleveland Clinic Cancer Center at Fairview Hospital, Moll Pavilion - Cleveland
- Cleveland Clinic Foundation - Cleveland
- Kettering Medical Center - Kettering
Florida
- Clermont Oncology Center - Clermont
- Cancer Care Centers of Brevard, Inc - Palm Bay
Iowa
- McFarland Clinic - Ames
- Helen G. Nassif Community Cancer Center - Cedar Rapids
Illinois
- Illinois Cancer Specialists - Niles
Indiana
- Fort Wayne Medical Oncology and Hematology, Inc - Fort Wayne
Kentucky
- Baptist Health Hardin Cancer Center - Elizabethtown
Maryland
- Frederick Health Hospital- James M Stockman Cancer Institute - Frederick
Massachusetts
- Beth Israel Lahey Health - Lahey Hospital & Medical Center (LHMC), Lahey Clinic Medical Center - Burlington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 621 participants |
| Start Date | 2025-02-03 |
| Est. Completion | 2029-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06712355
The ClinicalTrials.gov registry entry for NCT06712355 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 621 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 151-participant average among 25 other Extensive-stage Small-cell Lung Cancer trials with a reported enrollment target (311% higher). The listed sponsor is BioNTech SE, which has 53 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Extensive-stage Small-cell Lung Cancer appearing as the primary indexed condition, and to 4 interventions - of which Atezolizumab is the first listed.
NCT06712355 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Ohio, Florida, Iowa.
Frequently Asked Questions
What is clinical trial NCT06712355 about?
NCT06712355 is a clinical study titled "Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer". This is a Phase III, multisite, randomized, double-blinded study to investigate pumitamig (BNT327) combined with chemotherapy (etoposide/carboplatin) compared to atezolizumab combined with chemotherapy (etoposide/carboplatin) for the treatment of participants with previously untreated extensive-stag...
What is the current status of trial NCT06712355?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 621 participants. The study started on 2025-02-03. Estimated completion is 2029-03.
What conditions does trial NCT06712355 study?
This clinical trial studies the following conditions: Extensive-stage Small-cell Lung Cancer.
What interventions are being tested in trial NCT06712355?
The interventions under investigation include: Atezolizumab (DRUG), Pumitamig (DRUG), Etoposide (DRUG), Carboplatin (or cisplatin if carboplatin is not tolerated) (DRUG).
Who is sponsoring clinical trial NCT06712355?
This trial is sponsored by BioNTech SE, which has 53 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06712355 being conducted?
This trial has 20 study locations across Florida, Illinois, Indiana, Iowa, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Extensive-stage Small-cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)
RECRUITING · Phase 3
-
A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
RECRUITING · Phase 3
-
To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC
ACTIVE NOT RECRUITING · Phase 3
-
Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab
ACTIVE NOT RECRUITING · Phase 3
-
Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES)
RECRUITING · Phase 2
-
A Study of Valemetostat in Combination With Atezolizumab in People With Lung Cancer
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.